At this crucial time, when the need for effective and safe innovative medicines has never been greater, advances in basic science and technology carry the promise of remarkable therapeutic advances. However, while pharmaceutical companies spend vast sums on R&D, the number of new molecular entities licensed appears to be steadily diminishing. Barry Hardy's article talks about how the effective application of Knowledge Management (KM) tools can result in earlier and more complete understanding of risks attributable to newly-marketed medicines.        

Barry Hardy:
Building the Drug Safety Body of Knowledge to Enhance Confidence in Safety.